Payment overview · 2025
General Payments
$282.55
20 reported records · 3 companies
Healthcare provider profile · identity verified
Jeff Yang, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BROOKLYN, NY · NPI 1891441424
Verified facts
What the public records show
CMS Open Payments records show Jeff Yang, FNP-BC received $282.55 in general payments during 2025 across 20 reported records.
Gilead Sciences, Inc. accounted for 80.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $226.11 | 80.0% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.46 | 14.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.98 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $282.55 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
76 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 889 | 316 |
| Amlodipine Besylate | Amlodipine Besylate | 624 | 212 |
| Diclofenac Epolamine | Diclofenac Epolamine | 485 | 123 |
| Losartan Potassium | Losartan Potassium | 448 | 158 |
| Vascepa | Icosapent Ethyl | 439 | 115 |
| Metformin Hcl | Metformin Hcl | 375 | 113 |
| Omeprazole | Omeprazole | 299 | 125 |
| Meclizine Hcl | Meclizine Hcl | 273 | 128 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 83 |
| Ammonium Lactate | Ammonium Lactate | 254 | 89 |
| Naproxen | Naproxen | 252 | 129 |
| Fluticasone Propionate | Fluticasone Propionate | 238 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 82 |
| Mometasone Furoate | Mometasone Furoate | 222 | 93 |
| Diclofenac Sodium | Diclofenac Sodium | 212 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 61 |
| Alendronate Sodium | Alendronate Sodium | 198 | 64 |
| Azelastine Hcl | Azelastine Hcl | 173 | 63 |
| Jardiance | Empagliflozin | 166 | 49 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 164 | 72 |
| Raloxifene Hcl | Raloxifene Hcl | 162 | 49 |
| Trazodone Hcl | Trazodone Hcl | 162 | 70 |
| Simvastatin | Simvastatin | 161 | 48 |
| Montelukast Sodium | Montelukast Sodium | 156 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 149 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 137 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 41 |
| Finasteride | Finasteride | 127 | 48 |
| Donepezil Hcl | Donepezil Hcl | 112 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 34 |
| Januvia | Sitagliptin Phosphate | 106 | 26 |
| Azithromycin | Azithromycin | 104 | 91 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 91 | 31 |
| Allopurinol | Allopurinol | 89 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 89 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 25 |
| Hydrocortisone | Hydrocortisone | 88 | 31 |
| Vemlidy | Tenofovir Alafenamide | 86 | 13 |
| Glipizide Er | Glipizide | 81 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 79 | 35 |
| Gabapentin | Gabapentin | 78 | 41 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 76 | 48 |
| Farxiga | Dapagliflozin Propanediol | 74 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 27 |
| Lisinopril | Lisinopril | 71 | 25 |
| Atenolol | Atenolol | 66 | 23 |
| Ibuprofen | Ibuprofen | 66 | 48 |
| Famotidine | Famotidine | 65 | 24 |
| Meloxicam | Meloxicam | 65 | 24 |
| Clobetasol Propionate | Clobetasol Propionate | 62 | 20 |
| Nifedipine Er | Nifedipine | 61 | 16 |
| Halobetasol Propionate | Halobetasol Propionate | 60 | 22 |
| Tradjenta | Linagliptin | 60 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 17 |
| Bepotastine Besilate | Bepotastine Besilate | 57 | 22 |
| Glimepiride | Glimepiride | 53 | 17 |
| Alcohol Pads | Alcohol Antiseptic Pads | 49 | 16 |
| Clotrimazole | Clotrimazole | 49 | 26 |
| Loperamide | Loperamide Hcl | 43 | 28 |
| Irbesartan | Irbesartan | 40 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 13 |
| Carvedilol | Carvedilol | 39 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 23 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Celecoxib | Celecoxib | 35 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 15 |
| Restasis | Cyclosporine | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Prolia | Denosumab | 31 | 25 |
| Acarbose | Acarbose | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | 11 |
| Entecavir | Entecavir | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 26 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | 11 |
| Mupirocin | Mupirocin | 24 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Proctozone-Hc | Hydrocortisone | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 12 |
| Dutasteride | Dutasteride | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | 16 |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 19 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 16 |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Multaq | Dronedarone Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $282.55 · 20 records | Gilead Sciences, Inc. | AREXVY, BREZTRI, SHINGRIX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error